ClinicalTrials.gg
Not yet recruitingNCT07338630Updated Nov 19, 2026

Comparison of the Interscalene Block Alone Versus Combined With Superior Truncus Block During Shoulder Surgery in Diaphragmatic Function

An interventional study of Regional anesthesia in shoulder surgery in Diaphragm Issues, sponsored by Sohag University. Not yet recruiting. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Sohag University · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 19, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

Primarily, This study aims to compare between interscalene block alone versus combined with superior truncus block in producing diaphragmatic paralysis and Secondarily aims to evaluate

  1. Effect on the pulmonary function.
  2. Duration of the sensory and motor block.
  3. Postoperative analgesic consumption.
  4. Any complications or side effects during shoulder surgery.
Read the detailed description

Regional anesthesia is central to modern shoulder surgery because it provides excellent perioperative analgesia, reduces opioid consumption, and facilitates early rehabilitation. The interscalene brachial plexus block (ISB) has long been considered the gold-standard single-shot regional technique for shoulder procedures due to its reliable analgesia and surgical anesthesia. However, ISB commonly causes ipsilateral hemidiaphragmatic paresis (HDP) from unintended phrenic nerve blockade, which can produce clinically important declines in pulmonary function and may be poorly tolerated in patients with limited respiratory reserve.

To minimize phrenic involvement while preserving analgesic effectiveness, more selective approaches have been proposed. The superior trunk block (STB) - performed at the level where C5-C6 fibers form the superior trunk - aims to anesthetize the shoulder innervation more distally and thus reduce spread to the phrenic nerve. A landmark randomized trial and subsequent studies reported that STB provides analgesia comparable to ISB while greatly lowering the incidence of HDP (for example, ISB 71% vs STB 5% in one trial). Systematic reviews and meta-analyses since then have reinforced STB as an effective phrenic-sparing alternative for many shoulder procedures.

Despite encouraging data for STB, the literature is not entirely uniform. Some randomized trials and observational reports have found either reduced anesthetic quality with STB or smaller-than-expected reductions in phrenic involvement, particularly when block technique, local anesthetic volume, or patient anatomy differ. Moreover, combining blocks (for example, ISB with selective superior-trunk targeting or other modifications) has been proposed as a strategy to balance surgical anesthesia and respiratory safety, but comparative prospective data examining the effect of ISB alone versus ISB combined with STB on diaphragmatic function are limited. This uncertainty is important because even partial diaphragmatic paresis can degrade postoperative pulmonary mechanics and increase complications in vulnerable patients.

02

Conditions studied

  • Diaphragm Issues
03

In context

Lead sponsor

Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA () I, II physical status.
  • Aged between 20 and 65 years.
  • Male or female.
  • (BMI): 18-30 kg/m3.
  • Scheduled for shoulder surgery.

Exclusion criteria

Exclusion Criteria:

  • Allergy to local anesthetics.
  • Infection at the injection site.
  • Coagulation disorders.
  • Respiratory diseases ( Acute or Chronic) or Chest trauma.
  • Multiple traumatized patients.
  • Phrenic nerve injury
  • Heart failure, Cardiomyopathy.
  • Severe organ dysfunction
  • Patient refusal
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Interscalene block alone

    Interscalene block alone, we will inject 20 mL of 0.5 % bupivacaine plus 10 mL of 0.9 % normal saline around brachial plexus in the interscalene site under ultrasonograhy.

    Other: Regional anesthesia in shoulder surgery

  • Active comparator
    Interscalene block plus Superior truncus block

    1. We will inject 7 mL of 0.5 % bupivacaine plus 3 mL of 0.9 % normal saline ( Total amount 10 ml) around brachial plexus in the interscalene site under ultrasonograhy. 2. Also we will inject 13 mL of 0.5 % bupivacaine plus 7 mL of 0.9 % normal saline ( Total amount 20 ml) around Superior trunk of brachial plexus under ultrasonagraphy.

    Other: Regional anesthesia in shoulder surgery

Interventions

  • OtherRegional anesthesia in shoulder surgery

    Comparison of the interscalene block alone versus combined with superior truncus block during shoulder surgery in diaphragmatic function

06

What researchers measure

Primary outcomes

  1. Comparison between interscalene block alone versus combined with superior truncus block inproducing diaphragmatic paralysis

    Assessment of diaphragmatic function by diaphragm excursion (DE) and diaphragm thickening fraction (TF) will be measured both before and 30 minutes post-block. To measure DE, patients will be placed in a supine position, a convex transducer (3.5 \~ 5 MHz) will be used to scan while the right diaphragm through the hepatic window and the left diaphragm through the splenic window, which located near the anterior-axillary line. The craniocaudal movement of the diaphragm will be documented during deep inspiration using M-mode. * Complete diaphragmatic paralysis was defined as a 75% \~ 100% reduction in DE, including the occurrence of paradoxical movement. * Partial diaphragmatic paralysis was defined as a 25% \~ 75% reduction in DE. * No diaphragmatic paralysis was indicated by a DE reduction of less than 25%. To measure TF, patients will be placed in the same position with the head of the bed at 45°degree

    Time frame: Assessment of diaphragmatic function by diaphragm excursion (DE) and diaphragm thickening fraction (TF) will be measured both before and 30 minutes post-block.

Secondary outcomes

  1. Evaluation of the interscalene block alone versus combined with superior truncus block during shoulder surgery on the pulmonary function

    Assessment of pulmonary function by a handheld spirometer to measure forced vital capacity (FVC), forced expiratory volume ( FEV1, FEV2) with patients in an upright-seated position pre-block and 30 minutes post-block as well as 2-hours post-surgery. Spirometry will be performed three times, with the best effort recorded.

    Time frame: Assessment of pulmonary function by a handheld spirometer to measure forced vital capacity (FVC), forced expiratory volume ( FEV1, FEV2) with patients in an upright-seated position pre-block and 30 minutes post-block as well as 2-hours post-surgery

  2. Duration of the sensory and motor block onset, duration of the interscalene block alone versus combined with superior truncus block during shoulder surgery

    Sensory block onset time will be assessed at the time from local anesthetics injection by pinprick test which will be preformed with 22-gauge short beveled needle every minute. Sensory block recovery time will be noted every hour in 1st 6 hours, every 2 hours in 2nd 6 hours till recovery of all pain sensation in all dermatomes performed by pinprick test. Motor block onset time will be assessed at the time from local anesthetics injection until complete motor block which will be assessed by absence of voluntary movement on asking the patient to elevate his arm every minute. Motor block recovery time will be noted as the time of return of voluntary movement in the arm every hour in 1st 6 hours, every 2 hours in 2nd 6 hours.

    Time frame: Sensory, motor block onset time every minute. Sensory, Motor block duration every hour in 1st 6 hours , every 2 hours in 2nd 6 hours

  3. Evaluation of postoperative analgesic consumption

    Pain will be evaluated Postoperative immediately every hour in 1st 6 hours, every 2 hours in 2nd 6 hours by Visual Analogue Scale ( VAS) by instructing the patient to point to the position on the line to indicate how much pain they are currently feeling(10). * VAS (zero) indicates no pain. * VAS ( 1, 2, 3) indicates mild pain. * VAS ( 4, 5, 6) indicates moderate pain. * VAS ( 7, 8, 9, 10) : indicates severe pain.

    Time frame: 12 hours

  4. Evaluation of any complications or side effects during shoulder surgery

    Any local or systemic complications or side effects will be recorded every 2 hours post operative for 24 hours such as local anesthetic systemic toxicity (LAST), Horner's syndrome, hypoxia, dyspnea, pneumothorax and post-operative nausea and vomiting (PONV).

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Aug 2027; primary completion for Aug 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Apr 2026 → Aug 2027, primary completion Apr 2027 → Aug 2028 and completion Jun 2027 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Jan 14, 2026
StartEst.
Aug 1, 2027was Apr 2026
Primary completionEst.
Aug 1, 2028was Apr 2027
CompletionEst.
Dec 1, 2028was Jun 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Apr 1, 2026→Aug 1, 2027
Nov 19, 2026
Primary completion
Apr 1, 2027→Aug 1, 2028
Nov 19, 2026
Study completion
Jun 1, 2027→Dec 1, 2028
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Apr 1, 2026→Aug 1, 2027
    Primary completion Apr 1, 2027→Aug 1, 2028
    Study completion Jun 1, 2027→Dec 1, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07338630
Lead sponsor
Sohag University
Responsible party
Sherif Salah Ismail (Assistant lecturer of Anesthesia and ICU and Pain Management of Sohag University hospital, Sohag University) — Principal investigator
First posted
Jan 14, 2026
Start date
Aug 1, 2027 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Sherif Salah Ismail Assistant lecturer of Anesthesia
Contact
sherifsalah383@gmail.com
01007272718
El hadad Ali Mosa Professor of Anesthesia
Contact
01019816967
Sherif Salah Ismail Assistant lecturer of Anesthesia
principal investigator · Assistant lecturer of Anesthesia and ICU and Pain Management of Sohag University hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion